logo

IMVT

Immunovant·NASDAQ
--
--(--)
--
--(--)
5.43 / 10
Netural

Fundamental scrutiny indicates average standing (5.4/10). Favorable drivers: Inventory turnover ratio and Interest coverage ratio (EBIT / Interest expense) (%), balanced by issues in Net profit / Total profit (%) and PB-ROE. Investment outlook: guarded.

Fundamental(5.43)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.26
Score3/3
Weight25.47%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value54.19
Score3/3
Weight1.64%
1M Return0.88%
Inventory turnover ratio
Value126.83
Score2/3
Weight-2.12%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight20.44%
1M Return8.99%
PB-ROE
Value3.65
Score0/3
Weight7.28%
1M Return3.36%
Interest coverage ratio (EBIT / Interest expense) (%)
Value48.59
Score2/3
Weight-2.21%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value74.94
Score2/3
Weight0.19%
1M Return0.10%
Asset-MV
Value-0.51
Score3/3
Weight32.43%
1M Return11.94%
Net profit / Total profit (%)
Value100.22
Score1/3
Weight-2.73%
1M Return-1.59%
Cash-MV
Value-0.07
Score2/3
Weight19.62%
1M Return8.80%
Is IMVT undervalued or overvalued?
  • IMVT scores 5.43/10 on fundamentals and holds a Fair valuation at present. Backed by its -40.27% ROE, 0.00% net margin, -12.18 P/E ratio, 10.49 P/B ratio, and -27.60% earnings growth, these metrics solidify its Netural investment rating.